EUCTR2007-004757-28-GB进行中（未招募）1 期
A randomised controlled single-blind trial to compare intensive management vs standard care in early psoriatic arthritis - TICOPA
niversity of Leeds0 个研究点目标入组 206 人开始时间: 2008年3月14日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 206
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •Patients with the following characteristics are eligible for the study:
- •1.Patients with a diagnosis of psoriatic arthritis by a consultant Rheumatologist with less than 24 months disease duration.
- •2.Active disease defined by at least one tender or swollen joint or active enthesitis.
- •3.Age =18 years at the time of signing the informed consent form and either male or female patients.
- •4.Patient understands the objectives of the study and is able and willing to sign the Informed Consent Form.
- •5.Men and women of child bearing potential (WCBP) must use at least one adequate birth control measure for the duration of the study and should continue such precautions for 6 months after receiving the last dose of protocol treatment.
- •6.Adequate full blood count within 28 days before randomisation:
- •a.Haemoglobin count > 8.5 g/dL
- •b.White blood count (WBC) > 3.5 x 109/L
- •c.Absolute neutrophil count (ANC) > 1.5 x 109/L
- •d.Platelet count > 100 x 109/L
- •7.Adequate hepatobiliary function within 28 days before randomisation:
- •a. ALT and/or AST levels must be within 3 times the upper limit of normal range (ULN) for the laboratory conducting the test.
- •8.The patient must be able to adhere to the study visit schedule and other protocol requirements.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Patients will be excluded from this study for any of the following reasons:
- •1.Previous treatment for articular disease with disease modifying drugs (DMARDs) including, but not limited to, methotrexate, sulfasalazone, leflunomide,
- •2.Women who are pregnant, lactating or planning pregnancy within 6 months of their last dose of protocol treatment.
- •3.Use of any investigational agents within 4 weeks or within 5 half-lives of the investigational agent, whichever is longer, prior to randomisation.
研究者
相似试验
已完成
不适用
When reconstructing defects in the skull is it safer and more cost effective to use a patients own bone or a custom made titanium plateStrokeACTRN12612000353897Royal Perth Hospital64
终止
不适用
A single-blinded randomised controlled trial to evaluate the pre-treatment effect of two vaginal estradiol doses compared to no treatment on the quality of pap smears in post-menopausal women.Quality of post-menopausal pap smearsNew health condition. Please modify.Reproductive Health and Childbirth - Menstruation and menopauseACTRN12605000610639Family Planning NSW270
已完成
不适用
Effectiveness of interventions in improving continued exclusive breastfeeding in Brunei DarussalamISRCTN55245820Ministry of Health (Brunei)232
尚未招募
不适用
A clinical trial to study the effects and safety of 3 drugs in varied combinations, namely 1% Luliconazole cream plus 1% Ciclopirox Olamine cream, 1% Luliconazole cream plus 0.25% Amorolfine cream and 1% Luliconazole cream alone in the treatment of ringworm, a fungal infection of skin.CTRI/2022/12/048431SRM Medical College Hospital & Research Centre, SRMIST, Potheri
已完成
不适用
A single blind randomised controlled trial to determine the effectiveness and cost utility of manual chest physiotherapy techniques in the management of infective exacerbations of Chronic Obstructive Pulmonary DiseaseChronic Obstructive Pulmonary Disease (COPD)RespiratoryChronic obstructive pulmonary disease (COPD)ISRCTN13825248niversity of East Anglia (UK)550